Literature DB >> 19628654

Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.

Nicholas G Theodorakis1, Yining N Wang, Jian-Ming Wu, Mary A Maluccio, James V Sitzmann, Nicholas J Skill.   

Abstract

Portal hypertension (PHT) is a complication of liver cirrhosis and directly increases mortality and morbidity by increasing the propensity of venous hemorrhage. There are two main underlying causations for PHT, increased hepatic resistance and systemic hyperdynamic circulation. Both are related to localized aberrations in endothelial nitric oxide synthase (eNOS) function and NO biosynthesis. This study investigates the importance of eNOS and systemic hyperdynamic-associated hyperemia to better understand the pathophysiology of PHT. Wild-type and eNOS(-/-) mice were given the hepatotoxin CCl(4) for 4-12 wk. Hepatic fibrosis was determined histologically following collagen staining. Portal venous pressure, hepatic resistance, and hyperemia were determined by measuring splenic pulp pressure (SPP), hepatic portal-venous perfusion pressure (HPVPP), abdominal aortic flow (Qao), and portal venous flow (Qpv). Hepatic fibrosis developed equally in wild-type and eNOS(-/-) CCl(4)-exposed mice. SPP, Qao, and Qpv increased rapidly in wild-type CCl(4)-exposed mice, but HPVPP did not. In eNOS(-/-) CCl(4) mice, Qao was not increased, SPP was partially increased, and HPVPP and Qpv were increased nonsignificantly. We concluded that the systemic hyperemia component of hyperdynamic circulation is eNOS dependent and precedes increased changes in hepatic resistance. Alternative mechanisms, possibly involving cyclooxygenase, may contribute. eNOS maintains normal hepatic resistance following CCl(4)-induced fibrosis. Consequently, increased portal pressure following chronic CCl(4) exposure is linked to hyperdynamic circulation in wild-type mice and increased hepatic resistance in eNOS(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628654     DOI: 10.1152/ajpgi.00229.2009

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  9 in total

1.  Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.

Authors:  Amitava Das; Priyabrata Mukherjee; Sumit K Singla; Praveen Guturu; Megan C Frost; Debabrata Mukhopadhyay; Vijay H Shah; Chitta Ranjan Patra
Journal:  Nanotechnology       Date:  2010-07-08       Impact factor: 3.874

Review 2.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 3.  Current concepts on the role of nitric oxide in portal hypertension.

Authors:  Liang Shuo Hu; Jacob George; Jian Hua Wang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

4.  Murine study of portal hypertension associated endothelin-1 hypo-response.

Authors:  Nicholas Theodorakis; Mary Maluccio; Nicholas Skill
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

5.  Tumor necrosis factor alpha signaling in the development of experimental murine pre-hepatic portal hypertension.

Authors:  Nicholas G Theodorakis; Yining N Wang; Jianmin Wu; Mary A Maluccio; Nicholas J Skill
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-03-08

6.  Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis.

Authors:  Xin Zhao; Bo Deng; Xue-Yan Xu; Shi-Jun Yang; Tao Zhang; Yi-Jun Song; Xiao-Ting Liu; Yue-Qi Wang; Da-Yong Cai
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

7.  The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis.

Authors:  Mahmoud Elshal; Nashwa Abu-Elsaad; Amr El-Karef; Tarek Mostafa Ibrahim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-14       Impact factor: 3.000

8.  Metabolomic Characterization of Human Model of Liver Rejection Identifies Aberrancies Linked to Cyclooxygenase (COX) and Nitric Oxide Synthase (NOS).

Authors:  Nicholas J Skill; Campbell M Elliott; Brian Ceballos; Romil Saxena; Robert Pepin; Lisa Bettcher; Matthew Ellensberg; Daniel Raftery; Mary A Malucio; Burcin Ekser; Richard S Mangus; Chandrashekhar A Kubal
Journal:  Ann Transplant       Date:  2019-06-11       Impact factor: 1.530

9.  Salvianolic Acid B reducing portal hypertension depends on macrophages in isolated portal perfused rat livers with chronic hepatitis.

Authors:  Xin Zhao; Hongmei Jia; Shijun Yang; Yuetao Liu; Bo Deng; Xueyan Xu; Tao Zhang; Hang Zhou; Chengzhe Zu; He Yin; Ting Li; Yijun Song; Yueqi Wang; Pengtao Li; Zhongmei Zou; Dayong Cai
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-16       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.